Hydrophilic Regulator Hexapeptides as Inhibitors of Tumor Cell Multiple Drug Resistance
Abstract
Multiple drug resistance (MDR) of tumor cells to cytostatics is one of the most often and severe complications of chemotherapy in oncological patients. The phenomenon of MDR could be due to a sharp increase of the activity of the ATP-dependent transport proteins of the ABC system, that provides pumping of the drug from the cells to the extracellular space. Up to now, all the attempts to design agents preventing MDR were of no success. One of the prospective trends is the use of hydrophilic regulator hexapeptides. Three regulator hydrophilic hexapeptides of the linear and cyclic structure were used as the MDR modulators. The sensitivity of the tumor cells to various cytostatics in the presence of the peptides was determined by the MTT-test and the direct counting of the survived cells. The effect of the hexapeptides on MCF7, KB8-5 and PC3 cells was investigated. It was concluded that the hydrophilic hexapeptides of the linear and cyclic structure increased the sensitivity to doxorubicin (a cytostatic). The tumor cell MDR inhibition was mediated by the ATP-dependent transport protein MRP. Such a characteristic of the hexapeptides is of interest for their use as agents preventing MDR.
Conflicts of Interest Disclosure:
The authors declares that there is no conflict of interest.
Article info:
Date submitted: 13.05.2020
All authors have read and approved the final manuscript.
Peer review info:
"Antibiot Khimioter = Antibiotics and Chemotherapy" thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Editorial comment:
In case of any discrepancies in a text or the differences in its layout between the pdf-version of an article and its html-version the priority is given to the pdf-version.
About the Authors
V. V. Lebedev
Central Research Institute of Epidemiology, Moscow
Russian Federation
S. A. Novikov
Central Research Institute of Epidemiology, Moscow
Russian Federation
E. YU. Rybalkina
N. N. Blokhin Russian Scientific Centre of Oncology, Russian Academy of Medical Sciences, Moscow
Russian Federation
T. N. Zabotina
N. N. Blokhin Russian Scientific Centre of Oncology, Russian Academy of Medical Sciences, Moscow
Russian Federation
References
1. Krishna R., Mayer L. D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J Pharm. Sci. 2000; 11: 265-283.
2. Корыстов Ю. H., Лебедев В. В. u др. Гексапептид имунофан ингибирует MRP-зависимую множественную лекарственную устойчивость опухолевых клеток. Докл. АН. 2004; Т. 395, 6: 1-4.
3. Carmichael J., DeGraff W. G. et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 4: 936-942.
4. Лебедев В. В., Новиков С. А. Гидрофильный гексапептид имунофан - гиперактивный регулятор транспортных белков множественной лекарственной устойчивости. Бюл. экспер. биол. 2006; 142: 12: 649-651.
For citations:
Lebedev V.V.,
Novikov S.A.,
Rybalkina E.Yu.,
Zabotina T.N.
Hydrophilic Regulator Hexapeptides as Inhibitors of Tumor Cell Multiple Drug Resistance. Antibiot Khimioter = Antibiotics and Chemotherapy. 2010;55(1-2):3-5.
(In Russ.)
Views:
498